Hong Kong Pharma Digital Digital Tech Files 6-K: Material Info Update

Ticker: HKPD · Form: 6-K · Filed: Dec 17, 2025 · CIK: 2007702

Complexity: simple

Sentiment: neutral

Topics: foreign-issuer, corporate-update, material-information

TL;DR

**HKPDT just dropped a 6-K, meaning new important info is out.**

AI Summary

Hong Kong Pharma Digital Technology Holdings Ltd. filed a 6-K, which is a foreign private issuer report, indicating they are providing information that is material to investors. While the specific content of this 6-K is not detailed in the prompt, these filings typically include updates on financial results, corporate actions, or other significant events. For investors, this matters because it's a primary way the company communicates important developments that could affect its stock price and future performance.

Why It Matters

This filing signals that Hong Kong Pharma Digital Technology Holdings Ltd. has new, material information for investors, which could impact their investment decisions.

Risk Assessment

Risk Level: medium — The risk is medium because without the specific content of the 6-K, the impact on the stock is unknown, ranging from positive to negative.

Analyst Insight

An investor should immediately seek out the full 6-K filing to understand the specific details and implications of the material information being disclosed by Hong Kong Pharma Digital Technology Holdings Ltd. before making any investment decisions.

Key Players & Entities

FAQ

What specific information is contained within this 6-K filing?

The provided prompt does not detail the specific content of the 6-K filing from Hong Kong Pharma Digital Technology Holdings Ltd. To understand the filing, one would need to access the full document.

Why did Hong Kong Pharma Digital Technology Holdings Ltd. choose to file a 6-K instead of another SEC form?

Hong Kong Pharma Digital Technology Holdings Ltd. filed a 6-K because it is a foreign private issuer, and this form is used to furnish the SEC with material information that the company has made public in its home country or distributed to its shareholders.

What is the typical timeframe for a 6-K filing to be made public after the event it describes?

A 6-K filing must be furnished promptly after the information is made public in the company's home country or distributed to its shareholders, though 'promptly' is not strictly defined by a specific number of days.

How does a 6-K differ from a 10-K or 10-Q filing?

A 6-K is filed by foreign private issuers to report material information, while 10-K (annual reports) and 10-Q (quarterly reports) are filed by domestic U.S. companies for their periodic financial disclosures.

What kind of 'material information' is typically included in a 6-K filing?

Material information in a 6-K can include changes in management, significant acquisitions or dispositions, financial results, dividend declarations, or any other event that could reasonably affect an investor's decision.

Filing Stats: 2,040 words · 8 min read · ~7 pages · Grade level 20 · Accepted 2025-12-17 16:30:26

Key Financial Figures

Filing Documents

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2025 Commission File Number 001-42468 Hong Kong Pharma Digital Technology Holdings Limited (Registrant’s Name) Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon Hong Kong (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F INFORMATION CONTAINED IN THIS FORM 6-K REPORT Results of Annual General Meeting of Shareholders At the annual general meeting of shareholders (the “Meeting”) of Hong Kong Pharma Digital Technology Holdings Limited (the “Company”) convened on December 12, 2025 at 10:00 a.m., Hong Kong Time (December 11, 2025, at 9:00 p.m., Eastern Time), at Fl Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon, Hong Kong, the shareholders of the Company adopted resolutions approving all of the nine proposals considered at the Meeting. A total of 11,000,000 ordinary shares, par value US$0.001 per share (“Ordinary Shares”) of the Company, each of which is entitled to one (1) vote per share as of November 14, 2025, the record date, were outstanding. There were present in person or by proxy 7,185,876 Ordinary Shares voted at the Meeting, which represents approximately 65.32% of the votes of the outstanding Shares in the Company. The results of the votes were as follows: Proposal One RESOLVED, that the re-election of the following five members of the Company’s board of directors, each to serve until the next annual general meeting or until his/her respective successor is elected and duly qualified is hereby approved, ratified and confirmed. Nominees Votes Cast For Votes Against Votes Abstained/ Withheld Broker Non-Votes Chenyu Liang 7,182,498 3,373 5 - Lap Sun Wong 7,182,498 3,373 5 - Mike Yao Zhou 7,182,498 3,373 5 - Jingyan Wu 7,182,498 3,373 5 - Dr. Kam Leung Chan 7,182,498 3,373 5 - Proposal Two RESOLVED, that the re-appointment of Onestop Assurance PAC as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2026, and to authorize the Company’s board of directors (the “Board”) and/or the Audit Committee to fix such independent registered public accounting firm’s annual compensation be, and hereby is, authorized. For Against Abstain Broker Non-Votes 7,182,503 3,373 - - Proposal Three RESOLVED, by ordinary resolutions, to approve an increase of the authorized share capital of the Company from US$100,000 divided into 100,000,000 ordinary shares of par value of $0.001 each, to US$1,000,000 divided into 1,000,000,000 ordinary shares of par value of US$0.001. For Against Abstain Broker Non-Votes 7,171,003 14,873 - - 1 Proposal Four RESOLVED, subject to the approval and implementation of the Increase in Authorized Capital, by an ordinary resolutions, to approve an amendment of the authorized share capital of the Company (the “Share Capital Amendment”) from US$1,000,000 divided into 1,000,000,000 ordinary shares of par value of $0.001 each, to US$1,000,000 divided into 1,000,000,000 ordinary shares of par value of US$0.001 each (“Ordinary Shares”), comprising (i) 940,000,000 class A ordinary shares of par value of US$0.001 each (“Class A Ordinary Shares”) and (ii) 60,000,000 class B ordinary shares of par value of US$0.001 each (the “Class B Ordinary Shares”) by: (a) re-designating all issued and outstanding Ordinary Shares (being 11,000,000 Ordinary Shares) as a consequence of the resolutions above, into Class A Ordinary Shares with one (1) vote per share and with other rights attached to it in the Fourth Amended and Restated Memorandum and Articles of Association (hereinafter defined) on a one for one basis; (b) re-designating 60,000,000 authorized but unissued Ordinary Shares into 60,000,000 Class B Ordinary Shares with 50 votes per share and with other rights attached to it in the Fourth Amended and Restated Memorandum and Articles of Association on a one for one basis; (c) re-designating the remaining 929,000,000 authorized but unissued Ordinary Shares into Class A Ordinary Shares on a one for one basis; (d) as a consequence of the Share Capital Amendment, the authorized share capital of the Company will be changed from US$1,000,000 divided into 1,000,000,000 ordinary shares of par value of US$0.001 each, to US$1,000,000 divided into 1,000,000,000 Ordinary Shares, comprising (i) 940,000,000 Class A Ordinary Shares and (ii) 60,000,000 Class B Ordinary Shares; (e) to authorize the transfer agent and

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing